Boston Scientific price target lowered to $105 from $115 at RBC Capital

RBC Capital lowered the firm’s price target on Boston Scientific (BSX) to $105 from $115 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results for MedTech names. The firm notes that its intra-quarter due diligence suggests strong fundamentals and stable end markets, with no demand disruption in sight. RBC also believes that the current sentiment-driven dislocation is unwarranted, creating attractive opportunities across the landscape both into Q1 earnings season and longer-term. For the company, the firm also believes that its full-year guide as achievable and sees Boston Scientific as one of the premier Medtech companies with a strong multi-year double-digit growth trajectory supported by major upcoming product cycles.